)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
OssDsign (OSSD) investor relations material
OssDsign Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary19 Aug, 2025
Executive summary
Launched the 'Scale to Profit' growth strategy, supported by a CHF160 million (SEK 158 million) capital raise to fund expansion and achieve positive cash flow.
Achieved significant clinical milestones, including treating over 10,000 patients and publishing strong clinical evidence, such as 100% spinal fusion at 24 months in the TOP FUSION study and 88.4% fusion in complex patients.
Strong commercial progress in the US, with over 200 hospital approvals, a growing distributor network, and all sales derived from the US orthobiologics market.
Gross margin improved to 96.8% in Q2, reflecting operational efficiency and product scalability.
Adjusted EBIT loss narrowed to SEK -6.2 million in Q2, showing improved operating leverage.
Financial highlights
Q2 net sales: SEK 46.5 million, up 73% year-over-year at constant FX and 16% sequentially from Q1; reported growth at 56%.
Gross margin: 96.8% in Q2 (Q2 2024: 93.2%), 96.6% for H1 2025 (H1 2024: 93.4%).
Adjusted EBIT: SEK -6.2 million in Q2 (Q2 2024: SEK -15.3 million); H1 2025: SEK -11.8 million (H1 2024: SEK -27.3 million).
Cash and cash equivalents at period end: SEK 212.7 million, up from SEK 100.9 million at year-end 2024.
Some Q2 sales (~SEK 1.5 million, ~5% of growth) were pulled forward from Q3 due to early customer orders, slightly inflating Q2 results.
Outlook and guidance
Strategy targets over SEK 400 million in sales and positive cash flow by 2028, with plans to double the US sales force by 2026 and expand market access to 30% by 2028, covering 35 states.
R&D costs expected to rise in 2026 with the start of a large randomized controlled trial (RCT).
CapEx to continue in Q3 and Q4, with a larger impact possible in 2026 if the RCT is capitalized.
Strategic investments in marketing, manufacturing, and clinical trials to drive long-term growth and profitability.
What is the target sales by 2028?
Explain the temporary regulatory project costs.
Detail the plan to move production to the U.S.
How will doubling the sales force impact costs?
When will the large clinical trial start?
What is the plan to expand market access?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next OssDsign earnings date
Q3 20254 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
OssDsign AB designs, manufactures, and sells implants and material technology for bone regeneration. The company's products are used to treat bone defects in the hard palate and other areas as well as to support dental implants. The company has strategic relations with several companies across Europe and the US, and markets their products to customers all over the world. OssDsign's aim is to be an innovative and leading specialty pharma player within the fast growing bone reconstruction market by providing products that offer unique opportunities for superior clinical outcomes, thereby adding value for patients, healthcare providers and investors.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage